b0e77ab3b8
Pentagon-Agent: Vida <HEADLESS>
5 KiB
| type | title | author | url | date | domain | secondary_domains | format | status | priority | tags | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| source | CBT vs Antidepressant Continuation for Depression Relapse Prevention: Individual Participant Data Meta-analysis | Breedvelt, Warren, Segal, Kuyken, Bockting — JAMA Psychiatry | https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2780290 | 2021-08-01 | health | research-paper | unprocessed | medium |
|
Content
Individual participant data (IPD) meta-analysis from JAMA Psychiatry examining whether sequential psychological intervention during/after antidepressant tapering can substitute for antidepressant continuation in relapse prevention.
Study design: Selected RCTs comparing psychological intervention during/after antidepressant tapering vs. antidepressant monotherapy. IPD analysis allows examination of individual patient-level moderators.
Key findings:
- Sequential delivery of psychological intervention during/after tapering may be an effective relapse prevention strategy INSTEAD of long-term antidepressant use
- CBT and continued antidepressant medication (ADM-c) were BOTH superior to discontinued medication (ADM-d) in preventing relapse over 12 months
- CBT and continued medication did not differ significantly from each other in relapse prevention
- No moderators (clinical factors) were associated with differential risk of relapse — the CBT advantage holds across patient subgroups
Durability principle:
- CBT provides "enduring effects that extend beyond the end of treatment"
- CBT appears "as effective as keeping patients on medication" for relapse prevention
- The mechanism is skill acquisition: CBT teaches cognitive and behavioral strategies that patients retain after therapy ends
Relapse rate context:
- Antidepressant discontinuation (abrupt or rapid): ~34.81% at 6 months, ~45.12% at 12 months
- CBT after/during tapering: comparable protection to continued medication
Agent Notes
Why this matters: This is the key study for the continuous-treatment model differential durability finding. The contrast is stark: antidepressant discontinuation → high relapse; CBT completion → protection comparable to continued medication. This means BEHAVIORAL interventions in depression can substitute for continuous pharmacotherapy in a way that has NO equivalent in metabolic disease (you cannot do "GLP-1 skills training" that allows patients to maintain weight loss after drug cessation).
What surprised me: The finding that CBT is AS EFFECTIVE AS continued antidepressant medication in relapse prevention — not just better than abrupt discontinuation. This is a stronger durability claim than I expected.
What I expected but didn't find: Evidence that CBT durability is absolute (it's not — CBT patients still relapse, just less than antidepressant-discontinuation patients). The protection is relative, not absolute.
KB connections:
- Central evidence for the continuous-treatment model differential claim being developed this session
- Contrasts with GLP-1 rebound (Session 20) and food-as-medicine reversion (Session 17): metabolic/pharmacological interventions revert; behavioral cognitive interventions provide durable skill acquisition
- Connects to the mental health supply gap is widening not closing — if CBT is as effective as continued antidepressants for relapse prevention, the gap in CBT access is especially costly
Extraction hints:
- The differential durability principle is the key claim: behavioral/cognitive interventions acquire durable skills; pharmacological interventions require continuous delivery to maintain effect
- Claim candidate: "Cognitive behavioral therapy for depression provides durable protection against relapse comparable to continued antidepressant medication because therapy builds cognitive skills that persist after treatment ends — unlike pharmacological interventions whose benefits reverse within months of discontinuation"
- This claim would be explicitly positioned as the EXCEPTION to the continuous-treatment model, sharpening rather than disconfirming it
Context: 2021 study, but the evidence has been confirmed by the December 2025 Lancet Psychiatry NMA (76 RCTs, 17,000+ adults). The CBT durability finding has replicated across multiple meta-analyses — this is robust evidence.
Curator Notes
PRIMARY CONNECTION: Session 20's continuous-treatment model claim candidate; Lancet Psychiatry 2025 meta-analysis (archived separately) WHY ARCHIVED: Provides the mechanism explanation for why behavioral/cognitive interventions can substitute for continuous pharmacotherapy in depression while metabolic interventions cannot: skill acquisition vs. drug dependence EXTRACTION HINT: The skill-acquisition vs. continuous-delivery distinction is the conceptual contribution — not just that CBT works, but WHY it can be discontinued without full relapse (skills remain) vs. why antidepressants and GLP-1s cannot (no skill analog)